Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. advises clients across the life sciences sector, including emerging biotech companies, global pharma businesses, investors, academic institutions, and government entities. The firm handles corporate transactions, IP matters, regulatory strategy, and litigation affecting companies operating in the sector. In Boston, William Hicks, co-chair of the life sciences practice, represents issuers, investors, and investment banks in IPOs, cross-over investments, alternative public offerings, reverse mergers, and Form 10 transactions. Los Angeles-based Siegmund Gutman chairs the life sciences litigation practice and focuses on disputes involving biologic drug patents, other life sciences innovations, and Hatch-Waxman matters.
Legal 500 Editorial commentary
Accolades
Client satisfaction: Sector knowledge
Key clients
- QIAGEN N.V.
- Leerink Partners
- Standard BioTools
- Myriad Genetics
- Fulgent Genetics
- Amgen
- Eli Lilly
- Sanofi
- Gilead Sciences
- Breakout Ventures
Work highlights
Represents Eli Lilly in high-stakes intellectual property matters.
Representing Amgen in a series of high-profile cases under the Biologics Price Competition and Innovation Act.
Represented the underwriters in the $285M initial public offering (IPO) of LB Pharmaceuticals Inc.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
William Hicks; Siegmund Gutman
Other key lawyers
John Rudy; Cheryl Reicin